Andrew J. Armstrong, MD, MSc

home / authors / andrew-j-armstrong-md-msc

Articles

Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Approval of Olaparib Combo Impacts SOC in BRCA-Mutant Metastatic CRPC

June 1st 2023

Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Prostate Cancer

Judd W. Moul, MD;Tian Zhang, MD;Andrew J. Armstrong, MD, MSc;Joseph Lattanzi, MD

November 1st 2015

This management guide covers the treatment, diagnosis, and staging of prostate cancer.

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Andrew J. Armstrong, MD, MSc;Tomasz M. Beer, MD

April 27th 2012

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.

What to Order From the Prostate Cancer Treatment Menu?

Andrew J. Armstrong, MD, MSc;Judd W. Moul, MD;Daniel J. George, MD

January 17th 2012

These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them.

ASCO 2010: Selected Sessions in Renal Cell Carcinoma

Andrew J. Armstrong, MD, MSc

July 2nd 2010

In 2010, we have the clinical opportunity to choose among several “targeted” agents when treating patients with metastatic renal cell carcinoma (RCC).

New Generation of Targeted Therapies Show Promise in RCC

Andrew J. Armstrong, MD, MSc

June 7th 2010

In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, addressed the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.